Home > Healthcare > Medical Devices > Diagnostic Devices > Anthrax Vaccine Market
Anthrax Vaccine Market Size
- Report ID: GMI9546
- Published Date: May 2024
- Report Format: PDF
Anthrax Vaccine Market Size
Anthrax Vaccine Market was valued at USD 11.9 billion in 2023 and is anticipated to witness a CAGR of 5.4% over the analysis period. One of the primary drivers is the increasing awareness about anthrax as a potential bioterrorism threat, which has led to government initiatives and funding for anthrax vaccine development and procurement.
Additionally, the growing incidence of anthrax in livestock and humans, particularly in regions where the disease is endemic, is driving the demand for vaccines. Furthermore, the inclusion of anthrax vaccines in national immunization programs in some countries and the expansion of these programs to include more regions are expected to further fuel market growth.
Anthrax is a serious infectious disease caused by the bacterium Bacillus anthracis. It primarily affects animals but can also infect humans. Anthrax vaccines provide immunity against anthrax. The vaccines are generally safe and effective, although they can cause mild side effects such as soreness at the injection site, fever, and muscle aches.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Anthrax Vaccine Market Size in 2023: | USD 11.9 Billion |
| Forecast Period: | 2024 to 2032 |
| Forecast Period 2024 to 2032 CAGR: | 5.4% |
| 2032 Value Projection: | USD 19.1 Billion |
| Historical Data for: | 2021 - 2023 |
| No. of Pages: | 146 |
| Tables, Charts & Figures: | 256 |
| Segments covered: | Type, Application, End-use, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Frequently Asked Questions (FAQ) :
Anthrax Vaccine Market Scope
